How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bronchospasm-prevention-with-copd.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bronchospasm Prevention with COPD — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchospasm Prevention with COPD (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bronchospasm Prevention with COPD, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Arcapta Neohaler	INDACATEROL	Novartis	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2011-01-01
Spiriva	TIOTROPIUM BROMIDE	Boehringer Ingelheim	Anticholinergic	Muscarinic acetylcholine receptor M3	2004-01-01
Foradil	FORMOTEROL	Novartis	beta2-Adrenergic Agonist	Beta-2 adrenergic receptor	2001-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Flixotide	Flixotide	Mundipharma Research Limited		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Fluticason	Fluticason	Creighton University		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Serevent	Serevent	Fundacio Privada Mon Clinic Barcelona		Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Novartis · 2 drugs in Bronchospasm Prevention with COPD
Creighton University · 1 drug in Bronchospasm Prevention with COPD
Fundacio Privada Mon Clinic Barcelona · 1 drug in Bronchospasm Prevention with COPD
Boehringer Ingelheim · 1 drug in Bronchospasm Prevention with COPD
Mundipharma Research Limited · 1 drug in Bronchospasm Prevention with COPD
Teva Pharm · 1 drug in Bronchospasm Prevention with COPD
GSK (GlaxoSmithKline) · 1 drug in Bronchospasm Prevention with COPD

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bronchospasm Prevention with COPD:

Cite this brief

Drug Landscape (2026). Bronchospasm Prevention with COPD — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bronchospasm-prevention-with-copd. Accessed 2026-06-10.

Bronchospasm Prevention with COPD full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing